| Literature DB >> 21179352 |
Mona H Aburahma1, Hanan M El-Laithy, Yassin El-Said Hamza.
Abstract
The demand for sublingual tablets has been growing during the previous decades especially for drugs with extensive hepatic first-pass metabolism. Vinpocetine, a widely used neurotropic agent, has low oral bioavailability due to its poor aqueous solubility and marked first-pass metabolism. Accordingly, the aim of this work was to develop tablets for the sublingual delivery of vinpocetine. Initially, the feasibility of improving vinpocetineâs poor aqueous solubility by preparing kneaded solid systems of the drug with Î-Cyclodextrin and hydroxy acids (citric acid and tartaric acid) was assessed. The solid system with improved solubility and dissolution properties was incorporated into porous tablets that rapidly disintegrate permitting fast release of vinpocetine into the sublingual cavity. The pores were induced into these tablets by directly compressing the tabletsâ excipients with a sublimable material, either camphor or menthol, which was eventually sublimated leaving pores. The obtained results demonstrated that the tablets prepared using camphor attained sufficient mechanical strength for practical use together with rapid disintegration and dissolution. In vivo absorption study performed in rabbits indicated that the sublingual administration of the proposed porous tablets containing vinpocetine solid system with Î-Cyclodextrin and tartaric acid could be useful for therapeutic application.Entities:
Keywords: Hydroxy acids; Sublimable materials; Sublingual Porous tablets; Vinpocetine; β-Cyclodextrin
Year: 2010 PMID: 21179352 PMCID: PMC3002799 DOI: 10.3797/scipharm.0912-04
Source DB: PubMed Journal: Sci Pharm ISSN: 0036-8709
Fig. 1.In vitro dissolution profiles of vinpocetine (n=3) from its binary and ternary solid systems with β-cyclodextrin and hydroxy acids performed in phosphate buffer of pH 6.8 at 37±0.5°C. (a) Physical mixtures (b) Kneaded solid systems.(Vin: Vinpocetine; Cit: Citric acid; Tar: Tartaric acid).
Aqueous solubility (mg/ml ±SD, n=3) at 25°C, relative increment, and dissolution efficiency of vinpocetine from the prepared solid systems.(Vin: Vinpocetine; Tar: Tartaric acid; Cit: Citric acid).
| 0.02 ± 0.01 | 2.8 | 6.18 | 0.21 ± 0.08 | 26.7 | 15.19 | |
| 2.87 ± 0.1 | 359.0 | 13.86 | 5.64 ± 0.6 | 705.6 | 56.51 | |
| 2.46 ± 0.4 | 307.6 | 12.27 | 3.93 ± 0.3 | 491.8 | 22.00 | |
| 3.45 ± 0.2 | 431.2 | 16.71 | 7.30 ± 0.8 | 913.2 | 90.30 | |
| 2.92 ± 0.3 | 364.8 | 14.32 | 4.09 ± 0.4 | 512.2 | 34.42 | |
Relative Increment (R.I.) = ratio between drug solubility in the prepared solid system to that of drug alone.
Dissolution Efficiency (D.E.)= calculated from the area under the dissolution curve at 60 minutes.
The values between brackets represent the molar ratio of vinpocetine: βCD: hydroxy acid.
Fig. 2.Photographs of (a) Directly compressed vinpocetine tablet containing 10% of camphor before sublimation. (b) Top view, (c) Cross section, and (d) Magnified surface view after removal from vacuum oven.
Fig. 3.Photographs of (a) Directly compressed vinpocetine tablet containing 20% of camphor before sublimation. (b) Top view, (c) Cross section, and (d) Magnified surface view after removal from vacuum oven.
Fig. 4.Photographs of (a) Directly compressed vinpocetine tablet containing 10% of menthol before sublimation. (b) Top view, and (c) Side view after removal from vacuum oven.
Average weight, hardness, and friability of the prepared tablets.
| 200.09 ± 0.09 | 199.97 ± 0.04 | 6.96 ± 0.28 | 7.18 ± 0.17 | 0.13 | |
| 200.04 ± 1.02 | 180.07 ± 1.26 | 7.11 ± 0.13 | 5.28 ± 0.21 | 0.32 | |
| 199.94 ± 0.08 | 161.20 ± 1.27 | 7.01 ± 0.32 | 4.13 ± 0.43 | 0.65 | |
| 198.06 ± 1.12 | 183.40 ± 2.54 | 6.87 ± 0.45 | 1.71 ± 0.38 | 2.95 | |
| 200.03 ± 1.08 | Undetermined | ||||
| 200.10 ± 1.34 | 198.70 ± 1.27 | 6.11 ± 0.15 | 6.17 ± 0.31 | 0.16 | |
| 199.94 ± 1.10 | 181.20 ± 1.08 | 5.93 ± 0.53 | 4.23 ± 0.28 | 0.42 | |
| 200.01 ± 1.07 | 158.90 ± 0.57 | 5.89 ± 0.07 | 3.64 ± 0.21 | 0.72 | |
| 199.97 ± 1.21 | 184.81 ± 2.71 | 5.87 ± 0.42 | 0.98 ± 0.42 | 2.73 | |
| 199.95 ± 0.08 | Undetermined | ||||
Before sublimation;
After sublimation;
The tablets were broken after sublimation of 20% of menthol in vacuum oven.
Average drug content, wetting time, in vitro disintegration time, and oral disintegration time of the prepared tablets.
| 98.05 ± 0.84 | > 300 | 785.30 ± 16.08 | 447.42 ± 12.47 | |
| 95.49 ± 0.62 | 95.46 | 135.20 ± 8.24 | 63.49 ± 4.15 | |
| 93.82 ± 0.44 | 68.28 | 98.74 ± 4.21 | 54.12 ± 2.87 | |
| 94.53 ± 0.66 | 65.91 | 94.61 ± 6.18 | 47.45 ± 3.18 | |
| 94.07 ± 0.91 | 53.20 | 58.18 ± 5.23 | 38.93 ± 5.72 | |
| 97.18 ± 0.57 | 40.45 | 34.51 ± 3.47 | 23.21 ± 2.24 |
Fig. 5.Dissolution profile of vinpocetine (n = 3) from the prepared porous sublingual tablets performed in phosphate buffer of pH 6.8 at 37±0.5°C.
Fig. 6.Mean plasma concentrations of vinpocetine (mean ±SD, n = 12) following oral administration of Cavinton® tablets and the sublingual administration of porous tablets belonging to formulation F8.
Summary of pharmacokinetic parameters of vinpocetine following the administration of Cavinton® tablets and sublingual porous tablets of formulation F8.
| 0.26 ± 0.04 | 1.34 ± 0.63 | |
| 1.41 ± 0.80 | 1.08 ± 0.20 | |
| 0.82 ± 0.04 | 2.53 ± 0.40 | |
| – | 306.69% |
Mean± Standard deviation.
Composition of vinpocetine sublingual tablets.
| 41.66 | 200 | ||||
| 41.66 | 10 | 200 | |||
| 41.66 | 20 | 200 | |||
| 41.66 | 10 | 200 | |||
| 41.66 | 20 | 200 | |||
| 41.66 | 5 | 200 | |||
| 41.66 | 10 | 5 | 200 | ||
| 41.66 | 20 | 5 | 200 | ||
| 41.66 | 10 | 5 | 200 | ||
| 41.66 | 20 | 5 | 200 |
All batches contained 2% Kollidon CL as a bioadhesive agent, and 0.25% magnesium stearate as a lubricant.
Vinpocetine: βCD: tartaric acid kneaded solid system in 1:2:2 molar ratios equivalent to 5 mg vinpocetine.